Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - remifentanil hydrochloride, quantity: 2.194 mg (equivalent: remifentanil, qty 2 mg) - injection, powder for - excipient ingredients: glycine - ultiva for injection is indicated- as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery in adults; as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical but not cardiac procedures in children aged 1 to 12 years; for continuation as an analgesic into the immediate post-operative period under the close supervision of medically qualified persons trained in the use of anaesthetic drugs, during transition to longer acting analgesia following adult cardiac surgery-when endotracheal intubation and controlled ventillation are anticipated. for provision of analgesia and sedation in mechanically ventilated intensive care patients.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - remifentanil hydrochloride, quantity: 1.097 mg (equivalent: remifentanil, qty 1 mg) - injection, powder for - excipient ingredients: glycine - ultiva for injection is indicated- as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery in adults; as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical but not cardiac procedures in children aged 1 to 12 years; for continuation as an analgesic into the immediate post-operative period under the close supervision of medically qualified persons trained in the use of anaesthetic drugs, during transition to longer acting analgesia following adult cardiac surgery-when endotracheal intubation and controlled ventillation are anticipated. for provision of analgesia and sedation in mechanically ventilated intensive care patients.

Malta - angļu - Medicines Authority

brillpharma (ireland) limited inniscarra, main street, rathcoole, co. dublin, ireland - raloxifene hydrochloride - film-coated tablet - raloxifene hydrochloride 60 mg - sex hormones and modulators of the genital system

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - levocetirizine dihydrochloride (unii: sod6a38aga) (levocetirizine - unii:6u5ea9rt2o) - 1.2 chronic idiopathic urticaria levocetirizine dihydrochloride is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older. the use of levocetirizine dihydrochloride tablet is contraindicated in: 4.1 patients with known hypersensitivity patients with known hypersensitivity to levocetirizine or any of the ingredients of levocetirizine dihydrochloride tablets, or to cetirizine. observed reactions range from urticaria to anaphylaxis [see adverse reactions (6.2)]. 4.2 patients with end-stage renal disease patients with end-stage renal disease (clcr < 10 ml/min) and patients undergoing hemodialysis 4.3 pediatric patients with impaired renal function children 6 months to 11 years of age with impaired renal function 8.1 pregnancy risk summary available data from published literature and postmarketing experience with levocetirizine use in pregnant women ar

Lielbritānija - angļu - myHealthbox

fair-med healthcare gmbh - raloxifene hydrochloride - film-coated tablets - 60mg - selective oestrogen receptor modulator - it is indicated for the treatment and prevention of osteoporosis in postmenopausal women. a significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated.

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - raloxifene hydrochloride -

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

fresenius kabi usa, llc - mitoxantrone hydrochloride (unii: u6usw86rd0) (mitoxantrone - unii:bz114nvm5p) - mitoxantrone 2 mg in 1 ml - mitoxantrone injection, usp is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). mitoxantrone injection, usp is not indicated in the treatment of patients with primary progressive multiple sclerosis. the clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability.  mitoxantrone injection, usp in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. mi

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

watson laboratories, inc. - meclizine hydrochloride (unii: hdp7w44cio) (meclizine - unii:3l5tq84570) - tablet - 25 mg - prophylactic treatment and management of nausea and vomiting, and dizziness associated with motion sickness. meclizine hcl is contraindicated in individuals who have shown a previous hypersensitivity to it.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

rx pharma-pack, inc. - bupivacaine hydrochloride (unii: 7tqo7w3vt8) (bupivacaine - unii:y8335394ro) - bupivacaine hydrochloride anhydrous 5 mg in 1 ml - marcaine is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia. (see warnings .) experience with nonobstetrical surgical procedures in pregnant patients is not sufficient to recommend use of 0.75% concentration of marcaine in these patients. marcaine is not recommended for intravenous regional anesthesia (bier block). see warnings . the routes of administration and indicated marcaine concentrations are: - local infiltration - peripheral nerve block - retrobulbar block - sympathetic block - lumbar epidural 0.25%, 0.5%, and 0.75% (0.75% not for obstetrical anesthesia) - caudal - epidural test dose - dental blocks (see dosage and administration for additional information). standard textbooks should be consulted to determine the accepted procedures and techniques for the administration of marc

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

zoetis inc. - melarsomine dihydrochloride (unii: 9cva716q71) (melarsomine - unii:374gj0s41a) - melarsomine dihydrochloride 50 mg in 2 ml - diroban sterile powder for injection is indicated for the treatment of stabilized class 1a , 2b , and 3c heartworm disease caused by immature (4 month-old, stage l5 ) to mature adult infections of dirofilaria immitis in dogs. heartworm disease classification: the following parameters were used to classify the dogs in the clinical field trials for diroban. other parameters may  be considered. as a general rule, conservative treatment should be employed since heartworm disease is serious and potentially fatal. if there is evidence of a high worm burden, patients  should be categorized as class 3. a class 1: patients in this category are characterized as having asymptomatic to mild heartworm  disease. no radiographic signs or signs of anemia are evident. patients with mild disease may have subjective signs such as a general loss of condition, fatigue  on exercise, or occasional cough; however, no objective radiographic or other abnormal laboratory  parameters will be present. b class 2: patients in thi